BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
BioNxt Solutions Stock Performance
OTCMKTS:BNXTF traded up $0.01 during mid-day trading on Tuesday, reaching $0.17. The stock had a trading volume of 3,835 shares, compared to its average volume of 5,028. The stock has a market capitalization of $22.75 million, a P/E ratio of -3.34 and a beta of 0.85. BioNxt Solutions has a one year low of $0.10 and a one year high of $0.53. The firm has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $0.30.
BioNxt Solutions Company Profile
BioNxt Solutions Inc. is a biotechnology company developing drug-delivery technologies and pharmaceutical products. Its work includes sublingual dissolving films and other formulations intended to make medicines easier to administer and potentially improve how they are delivered. The company’s development programs include a sublingual formulation of cladribine, a medicine used to treat multiple sclerosis. BioNxt is also pursuing other drug-delivery and therapeutic projects; its products are in development rather than established as marketed treatments.
Read More
- Five stocks we like better than BioNxt Solutions
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for BioNxt Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNxt Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
